Rejuvenate Bio is an anti-aging company looking to leverage a gene therapy approach to chronic age-related diseases. According to Rejuvenate Bio aging is the greatest risk factor for many chronic diseases, and approximately 6 in 10 Americans suffer from a chronic disease. The ambition is to develop a gene therapy approach that can address multiple of these chronic diseases.
Feel welcome to share your own thoughts on this company in the comment section below as well. I will be happy to discuss and learn more about how you see their potential in this field.
The solution
Rejuvenate Bio is attempting to develop an ideal gene therapy treatment capable of addressing numerous chronic diseases, and the target they are aiming for here is a gene called FGF21.
According to Rejuvenate Bio FGF21 has been shown to activate key pathways associated with numerous chronic disease and as such has the potential to treat these chronic diseases. Adding to this it has been shown to be well tolerated in large clinical trials.
You can view their official pipeline in the below image from their website:
As we see on this pipeline FGF21 will be primarily indicated for chronic cardiac and metabolic diseases. The development of this solution seems to be around the pre-clinical stage, and as such it will be interesting to see the potential clinical trials to follow.
Gene therapy has already proven its merits by enabling the elimination of other rare chronic diseases such as beta-thalassemia for example. Although, it has also proven incredibly expensive and as such only rolled out slowly in countries that can afford such treatment to their citizens.
The company
Rejuvenate Bio was founded in 2017, and is headquartered in San Diego, CA, USA. The company was founded by George Church, Daniel Oliver, and Noah Davidson. The company was spun out of George Church’s lab at Harvard Medical School and the Wyss Institute for Biologically Inspired Engineering at Harvard University. George Church has very strong credentials, and interestingly was a founder of the human genome project.
In terms of funding we know that their most recent funding was raised in April 2021 from a series A round. Through this round they raised over $10M, and it was led by Kendall Capital Partners, which is a Boston-based company focused on early-stage biotech companies. As such it has been a while since their last capital injection, and we might see more funding rounds in the near future if they are looking to conduct clinical trials.
Read about more anti-aging companies on this website through this link.
